BioCentury | Jan 24, 2019
Emerging Company Profile

Caelus' microbes for metabolic syndrome

...to stop the leaks in metabolic syndrome. The Gastroenterology findings led to the development of CP-001...
...targets CP-001 to the small intestine. Caelus has completed a four-week Phase I trial of CP-001...
...Vedanta Biosciences Inc., Cambridge, Mass. Wageningen University and Research Centre, Wageningen, the Netherlands Mark Zipkin, Staff Writer CP-001 CP-002 Academic...
BioCentury | Feb 3, 2017
Company News

J&J, Caelus deal

...Janssen Human Microbiome Institute (JHMI) for use in identifying potential microbiome-based therapies. Caelus’ lead candidate, CP-001...
BioCentury | Feb 2, 2017
Company News

Caelus investment among J&J's microbiome deals

...access to JHMI’s computational resources for use in identifying potential microbiome-based therapies. Caelus’ lead candidate, CP-001...
...declined to provide additional terms of the deals. Jaime De Leon Caelus Health Johnson & Johnson Weizmann Institute of Science CP-001 DayTwo...
Items per page:
1 - 3 of 3